New Triple-Threat therapy trial targets tough HPV-Linked cancers
NCT ID NCT05280457
Summary
This study is testing a three-part treatment for adults with advanced head and neck cancer linked to HPV that has come back or spread. The treatment combines a DNA vaccine designed to target the virus, an immune-boosting drug (GX-I7), and an established immunotherapy (nivolumab). The main goal is to see if this combination can shrink tumors and control the cancer, while closely monitoring safety in a small group of up to 21 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yonsei University Health System, Severance Hospital
RECRUITINGSeoul, South Korea
Conditions
Explore the condition pages connected to this study.